China Intragastric Balloon Market Industry Trends and Forecast to 2034: Segmented by (Type, Filling, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
China · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$25.5 MnPlaceholder estimate
Estimate 2025$28.7 Mn9.3% of the global market
Projected 2034$84.2 Mn 193.3%Adds $55.5 Mn over 9 forecast years
CAGR 2025–203412.7%Faster than 67% of 173 Medical Devices markets here
Key players5Companies profiled
China is 9.32% of the global market.
In APAC, the largest is China (this report) at $28.7 Mn.
1 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The China Intragastric Balloon Market Analysis Executive Summary
Intragastric balloons are soft balloons placed in the stomach for a few months to help people eat less and lose weight without surgery.
Key segments of the intragastric Balloon market include type (Single Balloon, Dual Balloon and Swallowable Balloon) and filling (Saline-Filled and Gas-Filled).
China Intragastric Balloon market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
China Intragastric Balloon Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the intragastric Balloon market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the intragastric Balloon market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the intragastric Balloon market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Intragastric Balloon Market in China
The intragastric Balloon market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Intragastric Balloon Market in China
Intragastric Balloon in China: rules, payment and research
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered.[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.[2] ClinicalTrials.gov lists 1 study on Intragastric Balloon that is recruiting, active or about to start in China.[3] Obesity (adults): 9.3% of adults in 2024, the latest WHO figure for China.[4]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how intragastric Balloon products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in China.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Filling
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Allurion Technologies
7.2 Apollo Endosurgery
7.3 Spatz Medical
7.4 Obalon Therapeutics
7.5 Helioscopie
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The intragastric Balloon market can be segmented based on various criteria, including type, filling and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Intragastric Balloon right now, from free public sources.
How big is the Intragastric Balloon market in China?
Placeholder estimate: about $28.7 Mn in 2025, rising to about $84.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Intragastric Balloon market in China growing?
Placeholder estimate: about 12.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Intragastric Balloon market report cover?
The report splits the market by type (Single Balloon, Dual Balloon, Swallowable Balloon), filling (Saline-Filled, Gas-Filled) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Intragastric Balloon market?
Key players include Allurion Technologies, Apollo Endosurgery, Spatz Medical, Obalon Therapeutics and Helioscopie.
What is driving the Intragastric Balloon market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the intragastric Balloon market.
Who regulates Intragastric Balloon in China?
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Intragastric Balloon are running in China?
1 study is recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
What does WHO report for China?
Obesity (adults): 9.3% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.
How many people in China are 65 or older?
14.9% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.